Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MASP2 | O00187 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4416398 | 1.00 | MAOB (0.43) | MAOBMAOAMMP2MMP9ADAM17 | |
| SCHEMBL16401469 | 0.85 | MAOB (0.49) | MAOBMAOAMMP2MMP9ADAM17 | |
| SCHEMBL5400405 | 0.80 | MAOB (0.55) | MAOBMAOAMMP2MMP9ADAM17 | |
| SCHEMBL5400401 | 0.80 | MAOB (0.55) | MAOBMAOAMMP2MMP9ADAM17 | |
| SCHEMBL5180148 | 0.79 | TAS1R3 (0.40) | MAOBMAOA | |
| SCHEMBL12493203 | 0.78 | MAOB (0.46) | MAOBMAOAMMP2MMP9ADAM17 | |
| SCHEMBL4796989 | 0.78 | MAOB (0.46) | MAOBMAOAMMP2MMP9ADAM17 | |
| SCHEMBL6930389 | 0.78 | MAOB (0.53) | MAOBMAOAMMP2MMP9ADAM17 | |
| SCHEMBL4297619 | 0.77 | PTGER4 (0.43) | MAOBMAOAMMP2MMP9ADAM17 | |
| SCHEMBL2383875 | 0.76 | MEN1 (0.47) | MAOBMAOAADAM17NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376700-B2 | Methods of modifying N-termini of a peptide or protein using transferases | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150140605-A1 | ONE STEP N-TERMINAL TAGGING OF PROTEINS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2015-05-21 | — | — | US | disclosed |
| US-7608577-B2 | Peptidyl ketones as inhibitors of DPIV | OSI PHARMACEUTICALS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| EP-1434792-B1 | PEPTIDYL KETONES AS INHIBITORS OF DPIV | PROSIDION LTD (GB) | 2008-05-07 | — | — | EP | disclosed |
| US-7368576-B2 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | PROBIODRUG AG (DE) | 2008-05-06 | — | — | US | disclosed |
| US-7368421-B2 | Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis | PROBIODRUG AG (DE) | 2008-05-06 | — | — | US | disclosed |
| EP-1399471-B1 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2008-01-30 | — | — | EP | disclosed |
| US-20070207946-A1 | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | POSPISILIK ANDREW J | 2007-09-06 | — | — | US | disclosed |
| US-20060293248-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | PROBIODRUG AG | 2006-12-28 | — | — | US | disclosed |
| EP-1480961-B1 | GLUTAMINYL BASED DPIV INHIBITORS | PROSIDION LTD (GB) | 2006-12-27 | — | — | EP | disclosed |
| US-20030162820-A1 | Glutaminyl based DPIV inhibitors | PROSIDION LIMITED (GB) | 2003-08-28 | — | — | US | disclosed |
| US-20030148961-A1 | Peptidyl ketones as inhibitors of DPIV | PROSIDION LIMITED (GB) | 2003-08-07 | — | — | US | disclosed |
| US-20030130199-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | PROBIODRUG (DE) | 2003-07-10 | — | — | US | disclosed |
| US-20030125304-A1 | Substituted amino ketone compounds | PROSIDION LIMITED (GB) | 2003-07-03 | — | — | US | disclosed |
| US-20030119750-A1 | Use of dipeptidyl peptidase IV inhibitors | PROBIODRUG (DE) | 2003-06-26 | — | — | US | disclosed |
| WO-2003040174-A2 | SUBSTITUTED AMINO KETONE COMPOUNDS | PROBIODRUG AG (DE) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003033524-A2 | PEPTIDYL KETONES AS INHIBITORS OF DPIV | PROBIODRUG AG (DE) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003015775-A1 | NEW DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES FOR LOWERING BLOOD PRESSURE LEVELS | PROBIODRUG AG (DE) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003002596-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003002595-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES AS ANTI-CANCER AGENTS | PROBIODRUG AG (DE) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150140605-A1 | ONE STEP N-TERMINAL TAGGING OF PROTEINS | TRMT1, RNGTT, NSUN3 | MAOB 4056/4885MAOA 3746/4885MMP2 3346/4885 |
| US-20030148961-A1 | Peptidyl ketones as inhibitors of DPIV | GLS, SLC5A1, BCKDK | MAOB 4102/4885MAOA 4314/4885MMP2 1826/4885 |
| US-20060293248-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | DPP4, DPP3, DNPEP | MAOB 3893/4885MAOA 3856/4885MMP2 9/4885 |
| US-20030125304-A1 | Substituted amino ketone compounds | SLC5A1, GLS, GPR119 | MAOB 1239/4885MAOA 2502/4885MMP2 4711/4885 |
| US-20030130199-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | DPP4, DPP3, DNPEP | MAOB 3893/4885MAOA 3856/4885MMP2 9/4885 |
| US-20030119750-A1 | Use of dipeptidyl peptidase IV inhibitors | DPP4, DPP3, DPP7 | MAOB 1833/4885MAOA 1914/4885MMP2 28/4885 |
| US-20030162820-A1 | Glutaminyl based DPIV inhibitors | GLS, SLC7A11, GLS2 | MAOB 1790/4885MAOA 2516/4885MMP2 1401/4885 |
| US-20070207946-A1 | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | DPP4, DPP3, DPP9 | MAOB 2534/4885MAOA 2663/4885MMP2 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.